28466270|t|Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61
28466270|a|NMDA receptor signaling is critical for the development of synaptic plasticity, learning, and memory, and dysregulation of NMDAR signaling is implicated in a number of neurological disorders including schizophrenia (SZ). Previous work has demonstrated that the STriatal-Enriched protein tyrosine Phosphatase 61 kDa (STEP61) is elevated in human SZ postmortem cortical samples and after administration of psychotomimetics to cultures or mice. Here, we report that activation of synaptic NMDAR by bicuculline or D-serine results in the ubiquitination and proteasomal degradation of STEP61, and increased surface localization of GluN1 / GluN2B receptors. Moreover, bicuculline or D-serine treatments rescue the motor and cognitive deficits in MK-801 -treated mice and reduce STEP61 in mouse frontal cortex. These results suggest that STEP61 may contribute to the therapeutic effects of D-serine.
28466270	0	8	Synaptic	T030	C0039062
28466270	9	22	NMDA Receptor	T116,T192	C0080093
28466270	23	33	Activation	T043	C1514758
28466270	42	56	Ubiquitination	T044	C1519751
28466270	61	72	Degradation	T044	C0597297
28466270	76	82	STEP61	T116,T126	C1453844
28466270	83	96	NMDA receptor	T116,T192	C0080093
28466270	97	106	signaling	T043	C0037083
28466270	142	161	synaptic plasticity	T042	C0027880
28466270	163	171	learning	T041	C0023185
28466270	177	183	memory	T041	C0025260
28466270	189	202	dysregulation	T169	C0221099
28466270	206	211	NMDAR	T116,T192	C0080093
28466270	212	221	signaling	T043	C0037083
28466270	251	273	neurological disorders	T047	C0027765
28466270	284	297	schizophrenia	T048	C0036341
28466270	299	301	SZ	T048	C0036341
28466270	344	397	STriatal-Enriched protein tyrosine Phosphatase 61 kDa	T116,T126	C1453844
28466270	399	405	STEP61	T116,T126	C1453844
28466270	422	427	human	T016	C0086418
28466270	428	430	SZ	T048	C0036341
28466270	431	441	postmortem	T060	C0004398
28466270	442	450	cortical	T023	C0007776
28466270	451	458	samples	T077	C2347026
28466270	469	483	administration	T061	C1533734
28466270	487	503	psychotomimetics	UnknownType	C0684170
28466270	507	515	cultures	T059	C0040284
28466270	519	523	mice	T015	C0025929
28466270	546	556	activation	T043	C1514758
28466270	560	568	synaptic	T030	C0039062
28466270	569	574	NMDAR	T116,T192	C0080093
28466270	578	589	bicuculline	T109,T121	C0005372
28466270	593	601	D-serine	T116	C1880218
28466270	617	631	ubiquitination	T044	C1519751
28466270	636	659	proteasomal degradation	T044	C0597297
28466270	663	669	STEP61	T116,T126	C1447230
28466270	709	714	GluN1	T116,T192	C0061465
28466270	717	733	GluN2B receptors	T192	C1099474
28466270	745	756	bicuculline	T109,T121	C0005372
28466270	760	768	D-serine	T116	C1880218
28466270	769	779	treatments	T061	C0087111
28466270	791	796	motor	T033	C0521654
28466270	801	819	cognitive deficits	T048	C0009241
28466270	823	829	MK-801	T109,T121	C0813872
28466270	839	843	mice	T015	C0025929
28466270	855	861	STEP61	T116,T126	C1447230
28466270	865	870	mouse	T015	C0025929
28466270	871	885	frontal cortex	T023	C0016733
28466270	893	900	results	T169	C1274040
28466270	914	920	STEP61	T116,T126	C1447230
28466270	943	962	therapeutic effects	T201	C1527144
28466270	966	974	D-serine	T116	C1880218